Long non-coding RNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) has been reported to be implicated in tumor advancement [13], atherosclerosis [14], cerebral infarction [15], diabetes [16], and so on. Here, CDKN2B is linked to atherosclerosis.